Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | MAX | P61244 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131454 | 1.00 | ALOX5 (0.45) | ALOX5MEN1KMT2APIM1RAB9A | |
| SCHEMBL4122948 | 0.90 | ALOX5 (0.48) | ALOX5 | |
| SCHEMBL4122944 | 0.90 | ALOX5 (0.48) | ALOX5 | |
| SCHEMBL4140267 | 0.81 | ALOX5 (0.47) | ALOX5MEN1KMT2APIM1RAB9A | |
| SCHEMBL4140263 | 0.81 | ALOX5 (0.47) | ALOX5MEN1KMT2APIM1RAB9A | |
| SCHEMBL4120549 | 0.80 | PTP4A3 (0.47) | ALOX5MEN1KMT2APTPN1ALDH1A1 | |
| SCHEMBL4120552 | 0.80 | PTP4A3 (0.47) | ALOX5MEN1KMT2APTPN1ALDH1A1 | |
| SCHEMBL4635037 | 0.79 | FFAR1 (0.49) | ALOX5MEN1KMT2APIM1RAB9A | |
| SCHEMBL4635040 | 0.79 | FFAR1 (0.49) | ALOX5MEN1KMT2APIM1RAB9A | |
| SCHEMBL4120209 | 0.79 | AGTR1 (0.38) | ALOX5MEN1KMT2AMYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| EP-1934192-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2008-06-25 | — | — | EP | claimed |
| WO-2007032028-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-03-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | ALOX5 3505/4885MEN1 4075/4885KMT2A 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.